Exelixis, Inc.

Therapies ranging from small molecules to immuno-oncology drugs will make appearances at the 2025 American Society of Clinical Oncology meeting. These include drugs that are seen as having the potenti

Arcus Biosciences put a positive spin on Gilead Sciences’ decision not to opt in to further development of the HIF-2a inhibitor casdatifan in clear cell renal cell carcinoma (ccRCC) on 18 February, no

In its latest effort to identify drugs with price increases that had the biggest impact on US health care spending, the Institute for Clinical and Economic Review (ICER) included Merck & Co.’s Key

Arcus may be finding a new therapeutic direction for its cancer ambitions with its HIF-2a inhibitor casdatifan, reporting data from a Phase I/Ib study on 24 October that indicate the candidate may be